Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Treprostinil Sodium
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Corsair Completes Preclinical Program for Treprostinil Prodrug Patch
Details : TRX-248 transdermal system, a once-daily transdermal patch delivering treprostinil, a prostaglandin mimetic, for the treatment of Pulmonary Arterial Hypertension (PAH).
Product Name : TRX-248
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 17, 2025
Lead Product(s) : Treprostinil Sodium
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Treprostinil Prodrug
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : InstantGMP
Deal Size : Undisclosed
Deal Type : Partnership
Corsair Pharma Partners with InstantGMP® to Ensure Quality for Clinical Trials
Details : The partmership aims to create improved treatment options for patients with complex medical needs, including PAH treatment with its first product candidate CO-254, a prodrug of treprostinil.
Product Name : CO-254
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 28, 2025
Lead Product(s) : Treprostinil Prodrug
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : InstantGMP
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Treprostinil Prodrug
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : Junson Capital
Deal Size : $23.0 million
Deal Type : Series B Financing
Details : The proceeds will support the clinical advancement of Corsair’s lead product candidate, a prodrug of treprostinil delivered in a proprietary transdermal patch to treat Pulmonary Arterial Hypertension (PAH).
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
September 20, 2023
Lead Product(s) : Treprostinil Prodrug
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : Junson Capital
Deal Size : $23.0 million
Deal Type : Series B Financing